poisar

Stocks · News reference

ProKidney Q2 EPS $(0.15) Misses $(0.14) Estimate, Sales $150.000K Beat $149.000K Estimate

Benzinga Newsdesk

ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.14) by 7.14 percent. This is a 15.38 percent decrease over losses of $(0.13) per share from the

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

PROK
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Prokidney Corp.

    ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026

    ProKidney announced that eight abstracts, including one oral presentation, will be presented at ASN's Kidney Week 2026 in Denver. The abstracts present translational research and a pooled Phase 2 analysis supporting rilparencel's multifactorial mechanism of action for treating chronic kidney disease with type 2 diabetes, demonstrating kidney function stabilization and a strong safety profile.

    PROK
  2. SEC EDGAR

    8-K filing — PROKIDNEY CORP. (PROK)

    Filed: 2026-08-10 AccNo: 0001193125-26-342397 Size: 565 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

    PROK